Efficacy and Safety of Mavacamten and Aficamten in Obstructive and Non-obstructive Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis

By afschroeder • February 5, 2026

Ibrahim M, Kashif A, Arfin SMW, Mubeen M, Zafar A, Balach R, Musani MH, Greene SJ, Fonarow GC, Sohail MU. Efficacy and Safety of Mavacamten and Aficamten in Obstructive and Non-obstructive Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis. Crit Pathw Cardiol. 2026 Jan 30. doi: 10.1097/HPC.0000000000000418. Epub ahead of print. PMID: 41641607.

Tags: aficamten, cardiac myosin inhibitors, Cardiology/Epi, Hypertrophic cardiomyopathy, Left ventricular outflow tract gradient, Mavacamten, meta-analysis, Publications, Randomized Controlled Trials

Central Adiposity and Inflammation Mediate the Association Between Ultraprocessed Food Intake and Cardiovascular Disease Risk

Haidar A, Flynn S, Rikhi R, Watson KE, Wood AC, Shapiro MD. Central Adiposity and Inflammation Mediate the Association Between Ultraprocessed Food Intake and Cardiovascular[...]

Temporal and Regional Trends in Cardiovascular Mortality Associated With Diabetes Mellitus: A Nationwide Analysis From 1999 to 2020 in the United States

Ahmed S, Ahmed S, Ahmad E, Ashraf H, Akram U, Ahmad S, Uwishema O, Hassan IN, Ullah I, Ata F, Cheema AH, Alraies C, Fonarow[...]

A Polypill Strategy to Close the Heart Failure Treatment Gap

Fonarow GC, McMurray JJV. A Polypill Strategy to Close the Heart Failure Treatment Gap. JAMA Cardiol. 2026 Sep 30. doi: 10.1001/jamacardio.2026.3727. Epub ahead of print.[...]